The serum concentration of human kallikrein 10 represents a novel biomarker for ovarian cancer diagnosis and prognosis

Cancer Research

Volumn 63, Issue 4, 2003, Pages 807-811

  Luo, Liu Ying ^a,b   Katsaros, Dionyssios ^c   Scorilas, Andreas ^d   Fracchioli, Stefano ^c   Bellino, Roberto ^c   Van Gramberen, Marleen ^e   De Bruijn, Henk ^f   Henrik, Alfthan ^g   Stenman, Ulf Hakan ^g   Massobrio, Marco ^c   Van der Zee, Ate G J ^f   Vergote, Ignace ^e   Diamandis, Eleftherios P ^a,b  

^a MOUNT SINAI HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF TURIN   (Italy)

^d INSTITUTE OF NANOSCIENCE AND NANOTECHNOLOGY   (Greece)

^e UNIVERSITY OF LEUVEN   (Belgium)

^f UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^g HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

CA 125 ANTIGEN; KALLIKREIN; KALLIKREIN 10; SERINE PROTEINASE; TUMOR MARKER; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BLOOD LEVEL; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEATH; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DISEASE ASSOCIATION; EPITHELIUM CELL; FEMALE; GYNECOLOGIC DISEASE; HUMAN; HUMAN TISSUE; IMMUNOASSAY; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MULTICENTER STUDY; MULTIVARIATE ANALYSIS; OVARY CANCER; PRIORITY JOURNAL; PROGNOSIS; QUANTITATIVE ASSAY; SENSITIVITY AND SPECIFICITY; SERODIAGNOSIS; SERUM;

ADULT; AGED; CA-125 ANTIGEN; FEMALE; FLUOROIMMUNOASSAY; HUMANS; KALLIKREINS; MIDDLE AGED; NEOPLASM STAGING; OVARIAN NEOPLASMS; PROGNOSIS; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 0037442754     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Bast, R. C., Jr., Klug, T. L., St. John, E., Jenison, E., Niloff, J. M., Lazarus, H., Berkowitz, R. S., Leavitt, T., Griffiths, C. T., Parker. L., Zurawski, V. R., and Knapp, R. C. A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N. Engl. J. Med., 309, 883-887, 1983.
2. Bast, R. C., Jr., Xu. F. J., Yu, Y. H., Barnhill, S., Zhang, Z., and Mills, G. B. CA 125: the past and the future. Int. J. Biol. Markers, 13: 179-187, 1998.
3. Yousef, G. M., and Diamandis, E. P. The new human tissue kallikrein gene family: structure, function, and association to disease. Endocr. Rev., 22: 184-204, 2001.
4. Liu, X. L., Wazer, D. E., Watanabe, K., and Band, V. Identification of a novel serine protease-like gene, the expression of which is down-regulated during breast cancer progression. Cancer Res., 56: 3371-3379. 1996.
5. Luo, L., Herbrick, J. A., Scherer, S. W., Beatty, B., Squire, J., and Diamandis, E. P. Structural characterization and mapping of the normal epithelial cell-specific 1 gene. Biochem. Biophys. Res. Commun., 247: 580-586, 1998.
6. Goyal, J., Smith, K. M., Cowan, J. M., Wazer, D. E., Lee, S. W., and Band, V. The role for NES1 serine protease as a novel tumor suppressor. Cancer Res., 58: 4782-4786, 1998.
7. Luo, L. Y., Rajpert-De Meyts, E. R., Jung, K., and Diamandis, E. P. Expression of the normal epithelial cell-specific 1 (NES1; KLK10) candidate tumour suppressor gene in normal and malignant testicular tissue. Br. J. Cancer, 85: 220-224, 2001.
8. Luo, L, Y., Grass, L., Howarth, D. J. C., Thibault, P., On. H., and Diamandis, E. P. Immunofluorometric assay of human kallikrein 10 and its identification in biological fluids and tissues. Clin. Chem., 47: 237-246. 2001.
9. Luo, L. Y., Katsaros, D., Scorilas, A., Fracchioli, S., Piccinno, R., Rigault de la Longrais, I. A., Howarth, D. J., and Diamandis, E. P. Prognostic value of human kallikrein 10 expression in epithelial ovarian carcinoma. Clin. Cancer Res., 7: 2372-2379, 2001.
10. Luo, L. Y., Bunting, P., Scorilas, A., and Diamandis, E. P. Human kallikrein 10: a novel tumor marker for ovarian carcinoma? Clin. Chim. Acta, 306: 111-118. 2001.
11. Christopoulos, T. K., and Diamandis, E. P. Enzymatically amplified time-resolved fluorescence immunoassay with terbium chelates. Anal. Chem., 64: 342-346, 1992.
12. Yousef, G. M., Kyriakopoulou, L. G., Scorilas, A., Fracchioli, S., Ghiringhello, B., Zarghooni, M., Chang, A., Diamandis, M., Giardina, G., Hartwick, W. J., Richiardi, G., Massobrio, M., and Diamandis, E. P. Quantitative expression of the human kallikrein gene 9 (KLK9) in ovarian cancer: a new independent and favorable prognostic marker. Cancer Res., 61: 7811-7818, 2001.
13. Tuxen, M. K., Soletormos, G., and Dombernowsky, P. Tumor markers in the management of patients with ovarian cancer. Cancer Treat. Rev., 21: 215-245, 1995.
14. Mills, G. B., Bast, R. C., Jr., and Srivastava, S. Future for ovarian cancer screening: novel markers from emerging technologies of transcriptional profiling and proteomics. J. Natl. Cancer Inst. (Bethesda), 93: 1437-1439. 2001.
15. Woolas, R, P., Conaway, M. R., Xu, F., Jacobs, I. J., Yu, Y., Daly, L., Davies, A. P., O'Rriant, K., Berchuck, A., and Soper, J. T. Combinations of multiple serum markers are superior to individual assays for discriminating malignant from benign pelvic masses. Gynecol, Oncol., 59: 111-116, 1995.
16. Jacobs, I. J., Skates, S. J., MacDonald, N., Menon, U., Rosenthal, A. N., Davies, A. P., Woolas, R., Jeyarajah, A. R., Sibley, K., Lower, D. G., and Oram, D. H. Screening for ovarian cancer: a pilot randomised controlled trial. Lancet, 353: 1207-1210, 1999.
17. Skates, S. J., Xu, F. J., Yu, Y, H., Sjovall, K., Einhorn, N., Chang, Y., Bast, R. C., Jr., and Knapp, R. C. Toward an optimal algorithm for ovarian cancer screening with longitudinal tumor markers. Cancer (Phila.). 76: 2004-2010. 1995.
18. Diamandis, E. P., and Yousef, G, M. Human tissue kallikreins: a family of new cancer biomarkers. Clin. Chem., 48: 1198-1205. 2002.
19. Shigemasa, K., Underwood, L, J., Beard, J., Tanimoto, H., Ohama, K., Parmley. T. H., and O'Brien, T. J. Overexpression of testisin, a serine protease expressed by testicular germ cells, in epithelial ovarian tumor cells. J. Soc. Gynecol. Investig., 7: 358-362. 2000.
20. Tanimoto, H., Yan, Y., Clarke, J., Korourian, S., Shigernasa. K., Parmley, T. H., Parham, G, P., and O'Brien, T. J. Hepsin, a cell surface serine protease identified in hepatoma cells, is overexpressed in ovarian cancer. Cancer Res., 57: 2884-2887, 1997.
21. Hirahara, F., Miyagi, E., Nagashima, Y., Miyagi, Y., Yasumitsu, H., Koshikawa, N., Nakatani, Y., Nakazawa, T., Udagawa, K., Kitamura, H., Minaguchi, H., and Mityazaki, K. Differential expression of trypsin in human ovarian carcinomas and low-malignant-potential tumors. Gynecol. Oncol., 68: 162-165, 1998.
22. Mok, S. C., Chao, J., Skates, S., Wong, K., Yiu, G. K., Muto, M. G., Berkowitz, R. S., and Cramer, D. W. Prostasin, a potential serum marker for ovarian cancer: identification through microarray technology. J. Natl. Cancer Inst. (Bethesda), 93: 1458-1464. 2001.
23. Matrisian, L. M. Cancer biology: extracellular proteinases in malignancy. Curr. Biol., 9: R776-R778, 1999.
24. Aznavoorian, S., Murphy, A. N., Stetler-Stevenson, W. G., and Liotta, L. A. Molecular aspects of tumor cell invasion and metastasis. Cancer (Phila.), 71, 1368-1383. 1993.